Wegovy tablets vs Orforglipron — what’s coming and what’s available now

# Wegovy tablets vs Orforglipron — what’s coming and what’s available now

Orforglipron is a name you will hear increasingly in conversations about the future of weight management treatment. Eli Lilly, the company behind Mounjaro, has spent several years developing a small-molecule oral GLP-1 receptor agonist — and the trial results have attracted significant attention in endocrinology circles.

But as of June 2026, orforglipron is not approved in the UK. It is not available from any UK provider. It is not something you can be prescribed today.

Oral Wegovy tablets — approved by the MHRA on 11 June 2026 — are the only approved oral weight management GLP-1 medicine in the UK. This guide explains what orforglipron is, where it currently stands, and why anyone seeking an oral option right now has one clear answer.

> **Important:** Wegovy tablets are a prescription-only medicine. Always consult a qualified healthcare professional before starting or changing treatment. No information in this guide constitutes medical advice.

—

## What is orforglipron?

Orforglipron is an oral GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide — which is a peptide (a short chain of amino acids) — orforglipron is a small molecule. That distinction matters more than it might sound.

Peptide-based medicines like semaglutide are degraded in the digestive system when taken orally, which is why oral Wegovy requires the SNAC absorption technology to survive the stomach and why it must be taken on an empty stomach. Small molecules behave differently in the digestive tract — they are generally absorbed more reliably without special timing requirements.

Orforglipron can be taken with or without food. There is no fasting window. This is potentially a meaningful convenience advantage over oral Wegovy, for whom the 30-minutes-before-food requirement is one of the more frequently cited inconveniences.

—

## The ATTAIN trial results: what the data shows

Eli Lilly conducted Phase 3 trials of orforglipron under the ATTAIN programme. The headline weight loss result was approximately 9–10% average body weight reduction.

For context, oral Wegovy achieved 15.1% average weight loss in the OASIS 2 trial. Injectable semaglutide (Wegovy injection) achieved around 15% in the STEP 1 trial. Mounjaro (tirzepatide) achieved up to 22.5% at its highest dose in SURMOUNT-1.

On efficacy alone, orforglipron trails both oral and injectable semaglutide. Direct comparison between trials is always imperfect — different patient populations, different trial durations, different baseline weights — but the gap between 9–10% and 15% is large enough to be clinically meaningful.

The significant counterargument is convenience. If a medicine with 9–10% efficacy requires no fasting, no injection, and no careful morning routine management, some patients may find it more sustainable than a more effective medicine with adherence barriers. Sustained use of a slightly less potent medicine may, in some circumstances, deliver better real-world outcomes than intermittent use of a more potent one.

This is precisely the kind of trade-off that prescribers and patients will need to weigh together if and when orforglipron reaches the UK market.

—

## Why orforglipron is not available in the UK right now

Regulatory approval processes take time, and as of June 2026, orforglipron has not been submitted to or approved by the MHRA for use in the UK.

Eli Lilly has indicated plans to seek regulatory approval in multiple markets. The FDA process in the United States is ahead of the UK, with submissions expected in 2025 and potential approval there in 2026. UK MHRA approval — even if Eli Lilly applies promptly following any US approval — is unlikely before 2027 at the earliest. Regulatory review timelines, post-submission assessments, and commercial launch preparations mean there will be a further delay between submission and patients being able to access the medicine.

For anyone who wants an oral weight management tablet today, this is the critical point: orforglipron is not an option. It is a future possibility.

—

## The fasting question: orforglipron’s potential advantage

If orforglipron does reach the UK market, its no-fasting requirement could be genuinely significant for patient selection.

The oral Wegovy tablet must be taken on an empty stomach, at least 30 minutes before any food, drink (other than 120ml of plain water), or other oral medicines. For many people this works naturally into a morning routine — wake, take tablet, have a glass of water, go about your morning, then eat. For others, particularly those who take multiple morning medications, live active or unpredictable mornings, or simply struggle with delayed breakfasts, this requirement is a real barrier to adherence.

An oral GLP-1 that could be taken at any time with food would remove this friction entirely. Whether the 5–6 percentage point gap in average weight loss efficacy is outweighed by improved adherence is a question that real-world data — if orforglipron is eventually approved and widely used — would need to answer.

—

## What this means for the oral GLP-1 market in the UK

The arrival of oral Wegovy tablets in June 2026 represents the beginning of the oral GLP-1 category in the UK, not its entirety. The category is going to grow.

Orforglipron, if approved, would be the second oral GLP-1 option. Other companies are also developing small-molecule GLP-1 agonists at various stages of clinical development. The next three to five years are likely to see meaningful expansion in the number of oral weight management options available to UK patients.

For now, though, there is one approved oral option, and it is semaglutide. The competitive landscape that will eventually exist has not yet arrived.

CompareWegovyPrices.co.uk tracks not just current Wegovy tablet providers but also the broader oral GLP-1 pipeline. As orforglipron and other candidates move through UK regulatory processes, we will update our tracker accordingly.

—

## Your options if you want an oral weight management treatment today

If you are looking for an approved oral GLP-1 weight management medicine in the UK:

– **Oral Wegovy (semaglutide tablets)** — approved by MHRA on 11 June 2026, available via private prescription from verified UK providers. Starting dose 1.5mg, escalating to 25mg over approximately four months. Prices from £64 per month at verified providers. Daily tablet, taken 30 minutes before food.

– **Orforglipron** — not approved in the UK. Not available from any provider. No confirmed UK launch date. Do not accept any offer of orforglipron from a UK source — any such offer would involve an unapproved, unregulated product.

If you are needle-phobic or strongly prefer a tablet, oral Wegovy is the medically appropriate, legally available, clinically evidenced choice available to you today.

—

## Frequently asked questions

### What is orforglipron and why is everyone talking about it?

Orforglipron is an oral GLP-1 receptor agonist being developed by Eli Lilly. Unlike semaglutide, it is a small molecule rather than a peptide, which means it can be taken with food — no fasting required. Phase 3 trial results showed approximately 9–10% average body weight reduction. The interest stems from the convenience advantage it may offer, though UK regulatory approval is not expected before 2027 at the earliest.

### Is orforglipron available in the UK?

No. As of June 2026, orforglipron has not been approved by the MHRA and is not commercially available in the UK from any provider. If you encounter a UK source claiming to sell orforglipron, this is an unapproved product and should be avoided.

### How does orforglipron’s weight loss compare to oral Wegovy?

The ATTAIN Phase 3 trials of orforglipron showed approximately 9–10% average body weight reduction. Oral Wegovy (semaglutide) achieved 15.1% in the OASIS 2 trial. The difference is meaningful on average, though real-world adherence patterns may affect individual outcomes. Patients considering this trade-off should discuss it with a prescriber once orforglipron is approved.

### Why does orforglipron not require fasting but Wegovy tablets do?

Oral semaglutide is a peptide that would normally be degraded in the stomach. It uses SNAC absorption technology to pass through the stomach wall, which works best in an acidic, empty stomach — hence the fasting requirement. Orforglipron is a small molecule with a different absorption mechanism that does not depend on the same acidic environment, so food does not significantly impair its absorption.

### Should I wait for orforglipron rather than starting Wegovy tablets?

That is a clinical question best answered by your prescriber. From a practical standpoint: orforglipron is unlikely to be available in the UK before 2027, and weight management is generally most effective when started promptly with an approved, evidence-based medicine. Waiting an estimated year or more for an unapproved medicine is rarely the clinically recommended approach.

### Will CompareWegovyPrices.co.uk track orforglipron when it arrives?

Yes. The site’s Oral GLP-1 Tracker covers the broader oral weight management pipeline, including orforglipron’s UK regulatory progress. We will update provider listings and availability information as the UK landscape evolves.

—

*This article is for informational purposes only and does not constitute medical advice. Wegovy tablets are a prescription-only medicine available in the UK. Orforglipron is not approved in the UK as of June 2026. Always consult a registered UK healthcare professional before starting any weight management treatment. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk or Eli Lilly.*

Also in the pipeline: retatrutide

While orforglipron is Eli Lilly’s oral play, their injectable triple-agonist retatrutide showed even higher weight loss numbers in phase 2 (up to 24%). It is also not yet approved in the UK but represents the next frontier beyond both oral semaglutide and orforglipron. See our full retatrutide UK guide and the complete weight loss drug pipeline tracker for all upcoming options in one place.